{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:16:04Z","timestamp":1785453364841,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In the European LeukemiaNet (ELN) 2022 recommendations, myelodysplasia-related (MR) gene mutations were classified as a novel adverse prognostic category for intensively treated acute myeloid leukemia (AML). To assess the prognostic impact of individual MR genes within the ELN, clinical, cytogenetic, and molecular data from 4,978 intensively treated AML patients were analyzed. Remission rates and survival outcomes were evaluated. For analyses in context of ELN2022 classification, patients carrying an MR mutation were excluded from the adverse group and analyzed separately; those with co-occurring favorable or intermediate features remained in their respective groups. Overall, 1698 patients (34.1%) harbored at least one MR mutation. Lower complete remission rates were observed in MR-mutated cases (65.7% vs 77.7%;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) along with shorter event-free (HR 1.45;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), relapse-free (HR 1.33;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), and overall survival (HR 1.45;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) were recorded. Gene-specific prognostic patterns emerged:\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>RUNX1<\/jats:italic>\n                    ,\n                    <jats:italic>SF3B1<\/jats:italic>\n                    , and\n                    <jats:italic>U2AF1<\/jats:italic>\n                    mutations associated with adverse risk-like outcomes;\n                    <jats:italic>SRSF2<\/jats:italic>\n                    and\n                    <jats:italic>STAG2<\/jats:italic>\n                    aligned with intermediate-risk;\n                    <jats:italic>BCOR<\/jats:italic>\n                    ,\n                    <jats:italic>EZH2<\/jats:italic>\n                    , and\n                    <jats:italic>ZRSR2<\/jats:italic>\n                    did not differ significantly from intermediate or adverse risk. These findings from a large cooperative cohort highlight prognostic heterogeneity among MR mutations and suggest that SRSF2 and STAG2 mutations are associated with less adverse risk patterns, comparable to intermediate-risk.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02781-6","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:58:21Z","timestamp":1761559101000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1175-2406","authenticated-orcid":false,"given":"Marius","family":"Bill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-2823","authenticated-orcid":false,"given":"Jan-Niklas","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-2047","authenticated-orcid":false,"given":"Maximillian-Alexander","family":"R\u00f6hnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7364-5526","authenticated-orcid":false,"given":"Christian","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3920-7490","authenticated-orcid":false,"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-4894","authenticated-orcid":false,"given":"Sebastian","family":"Stasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0065-9481","authenticated-orcid":false,"given":"Alexander A.","family":"Wurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scholl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-8988","authenticated-orcid":false,"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-5502","authenticated-orcid":false,"given":"Bernhard","family":"W\u00f6rmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-9419","authenticated-orcid":false,"given":"Dennis","family":"G\u00f6rlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sauerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-8844","authenticated-orcid":false,"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sch\u00e4fer-Eckart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5259-4651","authenticated-orcid":false,"given":"Stefan W.","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-8940","authenticated-orcid":false,"given":"Maher","family":"Hanoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Fransecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Braess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-293X","authenticated-orcid":false,"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5890-5510","authenticated-orcid":false,"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6152","authenticated-orcid":false,"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-834X","authenticated-orcid":false,"given":"Claudia D.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2248-0557","authenticated-orcid":false,"given":"Jan","family":"V\u00e1lka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"\u0160r\u00e1mek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6460-2471","authenticated-orcid":false,"given":"Barbora","family":"Weinbergerova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3548","authenticated-orcid":false,"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-0753","authenticated-orcid":false,"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-0261","authenticated-orcid":false,"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-9432","authenticated-orcid":false,"given":"Tobias","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"2781_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2781_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"2781_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2781_CR4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood"},{"key":"2781_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00774-7","volume":"13","author":"XC Tsai","year":"2023","unstructured":"Tsai XC, Sun KJ, Lo MY, Tien FM, Kuo YY, Tseng MH, et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J. 2023;13:4.","journal-title":"Blood Cancer J"},{"key":"2781_CR6","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1182\/bloodadvances.2019001349","volume":"4","author":"C Gardin","year":"2020","unstructured":"Gardin C, Pautas C, Fournier E, Itzykson R, Lemasle E, Bourhis JH, et al. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020;4:1942\u20139.","journal-title":"Blood Adv"},{"key":"2781_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41375-023-01846-8","volume":"37","author":"K Mr\u00f3zek","year":"2023","unstructured":"Mr\u00f3zek K, Kohlschmidt J, Blachly JS, Nicolet D, Carroll AJ, Archer KJ, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37:788\u201398.","journal-title":"Leukemia"},{"key":"2781_CR8","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","volume":"37","author":"C Rausch","year":"2023","unstructured":"Rausch C, Rothenberg-Thurley M, Dufour A, Schneider S, Gittinger H, Sauerland C, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37:1234\u201344.","journal-title":"Leukemia"},{"key":"2781_CR9","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/bloodadvances.2024013304","volume":"25","author":"L Ruhnke","year":"2025","unstructured":"Ruhnke L, Bill M, Zukunft S, Eckardt JN, Sch\u00e4fer S, Stasik S, et al. Validation of the Revised 2022 European LeukemiaNet Risk Stratification in Adult Patients with Acute Myeloid Leukemia. Blood Adv. 2025;25:1392\u2013404.","journal-title":"Blood Adv"},{"key":"2781_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00790-1","volume":"13","author":"JN Eckardt","year":"2023","unstructured":"Eckardt JN, Stasik S, R\u00f6llig C, Sauer T, Scholl S, Hochhaus A, et al. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J. 2023;13:18.","journal-title":"Blood Cancer J"},{"key":"2781_CR11","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","volume":"118","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mr\u00f3zek K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118:6920\u20139.","journal-title":"Blood"},{"key":"2781_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2014.114157","volume":"100","author":"P Paschka","year":"2015","unstructured":"Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, et al. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica. 2015;100:324\u201330.","journal-title":"Haematologica"},{"key":"2781_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","volume":"29","author":"VI Gaidzik","year":"2011","unstructured":"Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, R\u00f6ck J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29:1364\u201372.","journal-title":"J Clin Oncol"},{"key":"2781_CR14","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, R\u00f6llig C, Soucek S, Kramer M, Thiede C, Mohr B, et al. Cytarabine dose of 36 g\/m\u00b2 compared with 12 g\/m\u00b2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011;29:2696\u2013702.","journal-title":"J Clin Oncol"},{"key":"2781_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/JCO.2013.54.4973","volume":"33","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Bornh\u00e4user M, Kramer M, Thiede C, Ho AD, Kr\u00e4mer A, et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. J Clin Oncol. 2015;33:403\u201310. 10.","journal-title":"J Clin Oncol"},{"key":"2781_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdy030","volume":"29","author":"C R\u00f6llig","year":"2018","unstructured":"R\u00f6llig C, Kramer M, Gabrecht M, H\u00e4nel M, Herbst R, Kaiser U, et al. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. Ann Oncol. 2018;29:973\u20138.","journal-title":"Ann Oncol"},{"key":"2781_CR17","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","volume":"35","author":"C R\u00f6llig","year":"2021","unstructured":"R\u00f6llig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35:2517\u201325.","journal-title":"Leukemia"},{"key":"2781_CR18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, D\u00f6hner K, Krauter J, Fr\u00f6hling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909\u201318.","journal-title":"N Engl J Med"},{"key":"2781_CR19","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","volume":"18","author":"RF Schlenk","year":"2004","unstructured":"Schlenk RF, Fr\u00f6hling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia. 2004;18:1798\u2013803.","journal-title":"Leukemia"},{"key":"2781_CR20","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","volume":"28","author":"RF Schlenk","year":"2010","unstructured":"Schlenk RF, D\u00f6hner K, Mack S, Stoppel M, Kir\u00e1ly F, G\u00f6tze K, et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol. 2010;28:4642\u20138.","journal-title":"J Clin Oncol"},{"key":"2781_CR21","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/leu.2016.25","volume":"30","author":"U Krug","year":"2016","unstructured":"Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, M\u00fcller-Tidow C, et al. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia. 2016;30:1230\u20136.","journal-title":"Leukemia"},{"key":"2781_CR22","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41375-018-0268-9","volume":"32","author":"J Braess","year":"2018","unstructured":"Braess J, Amler S, Kreuzer K-A, Spiekermann K, Lindemann HW, Lengfelder E, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia\u2014a phase 3 study. Leukemia. 2018;32:2558\u201371.","journal-title":"Leukemia"},{"key":"2781_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.27510","volume":"100","author":"C R\u00e9cher","year":"2025","unstructured":"R\u00e9cher C, Dumas PY, B\u00e9rard E, Tavitian S, Leguay T, Galtier J, et al. Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries. Am J Hematol. 2025;100:23\u201332.","journal-title":"Am J Hematol"},{"key":"2781_CR24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"2781_CR25","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41375-023-02016-6","volume":"37","author":"JN Eckardt","year":"2023","unstructured":"Eckardt JN, Bill M, Rausch C, Metzeler K, Spiekermann K, Stasik S, et al. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification. Leukemia. 2023;37:2282\u20135.","journal-title":"Leukemia"},{"key":"2781_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70060","volume":"9","author":"S Cocciardi","year":"2025","unstructured":"Cocciardi S, Saadati M, Wei\u00df N, Sp\u00e4th D, Kapp-Schwoerer S, Schneider I, et al. Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML. Hemasphere. 2025;9:e70060.","journal-title":"Hemasphere"},{"key":"2781_CR27","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","volume":"34","author":"T Herold","year":"2020","unstructured":"Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34:3161\u201372.","journal-title":"Leukemia"},{"key":"2781_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ng.3756","volume":"49","author":"M Gerstung","year":"2017","unstructured":"Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, et al. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49:332\u201340.","journal-title":"Nat Genet"},{"key":"2781_CR29","doi-asserted-by":"crossref","unstructured":"Mecklenbrauck R, Borchert N, Gabdoulline R, Poll P, Funke C, Brandes M, et al. Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemia. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02622-6"},{"key":"2781_CR30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41375-020-0839-4","volume":"34","author":"SA Bamopoulos","year":"2020","unstructured":"Bamopoulos SA, Batcha AMN, Jurinovic V, Rothenberg-Thurley M, Janke H, Ksienzyk B, et al. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020;34:2621\u201334.","journal-title":"Leukemia"},{"key":"2781_CR31","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.3324\/haematol.2019.222323","volume":"105","author":"S Stasik","year":"2020","unstructured":"Stasik S, Middeke JM, Kramer M, R\u00f6llig C, Kr\u00e4mer A, Scholl S, et al. EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia. Haematologica. 2020;105:e228\u2013e231.","journal-title":"Haematologica"},{"key":"2781_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02781-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:04:16Z","timestamp":1767985456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2781"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02781-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CT is co-owner of Agendix GmbH, a company performing molecular analysis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}